Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity

NCT04722640 is registered in ClinicalTrials.gov with Istituto Clinico Humanitas as lead sponsor.

NCT NCT04722640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04722640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
Lead sponsor
Istituto Clinico Humanitas
Phase
Phase 4
Overall status
Unknown status
Start date
January 25, 2021
Completion date
January 31, 2022
Enrollment
240 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis